Jaguar Health Inc. $(JAGX)$ has announced an extension of the maturity date for its convertible promissory notes from the recent bridge financing. The new maturity date is set for January 30, 2026, extending from the previous date of June 30, 2025. This change affects approximately $2.57 million in aggregate principal amount of the notes, which were part of a $3.448 million bridge financing deal that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million of the original financing into equity. CEO Lisa Conte expressed satisfaction with the agreement, highlighting the investors' commitment to supporting Jaguar's development programs for its plant-based medicine, crofelemer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.